LONDON, April 11, 2018 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory
Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) Provides Clinical Development Update
Verona Pharma Provides Clinical Development Update Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CF LONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) — Verona Pharma plc